Trials / Completed
CompletedNCT04399577
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
Detailed description
39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Candida antigen | Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2019-03-03
- Completion
- 2019-09-03
- First posted
- 2020-05-22
- Last updated
- 2020-05-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04399577. Inclusion in this directory is not an endorsement.